OBJECTIVE: To describe real-life dosing patterns in children with growth hormone deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS) receiving growth hormone (GH) and enrolled in the NordiNet International Outcome Study (IOS; Nbib960128) between 2006 and 2016. DESIGN: This non-interventional, multicentre study included paediatric patients diagnosed with GHD (isolated (IGHD) or multiple pituitary hormone deficiency (MPHD)), born SGA or with TS and treated according to everyday clinical practice from the Czech Republic (IGHD/MPHD/SGA/TS: n = 425/61/316/119), France (n = 1404/188/970/206), Germany (n = 2603/351/1387/411) and the UK (n = 259/60/87/35). METHODS: GH dosing was compared descriptively across countries and indications. Proportions of patients by GH dose group (low/medium/high) or GH dose change (decrease/increase/no change) during years 1 and 2 were also evaluated across countries and indications. RESULTS: In the Czech Republic, GH dosing was generally within recommended levels. In France, average GH doses were higher for patients with IGHD, MPHD and SGA than in other countries. GH doses in TS tended to be at the lower end of the recommended label range, especially in Germany and the UK; the majority of patients were in the low-dose group. A significant inverse association between baseline height standard deviation score and GH dose was shown (P < 0.05); shorter patients received higher doses. Changes in GH dose, particularly increases, were more common in the second (40%) than in the first year (25%). CONCLUSIONS: GH dosing varies considerably across countries and indications. In particular, almost half of girls with TS received GH doses below practice guidelines and label recommendations.

2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Alder Hey Children's NHS Foundation Trust Liverpool UK

Center for Chronic Sick Children Institute for Experimental Paediatric Endocrinology Charité Universitätsmedizin Berlin Berlin Germany

Department of Paediatric Endocrinology Hôpital des Enfants Toulouse France

Epidemiology Novo Nordisk A S Søborg Denmark

Novo Nordisk Health Care AG Zurich Switzerland

Zobrazit více v PubMed

Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocrine Development 2010. 18 92–108. (10.1159/000316130) PubMed DOI

Growth Hormone Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. Journal of Clinical Endocrinology and Metabolism 2000. 85 3990–3993. (10.1210/jcem.85.11.6984) PubMed DOI

Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. Journal of Clinical Endocrinology and Metabolism 2007. 92 804–810. (10.1210/jc.2006-2017) PubMed DOI

Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. Journal of Clinical Endocrinology and Metabolism 2007. 92 10–25. (10.1210/jc.2006-1374) PubMed DOI

Novo Nordisk, Bagsvaerd, Denmark. Norditropin® Summary of Product Characteristics, 2015.

Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Journal of Pediatrics 2003. 143 415–421. (10.1067/S0022-3476(03)00246-4) PubMed DOI

van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwe CW, Reeser HM, et al. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone. Journal of Clinical Endocrinology and Metabolism 1996. 81 4013–4021. (10.1210/jc.81.11.4013) PubMed DOI

Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. Journal of Clinical Endocrinology and Metabolism 2003. 88 3584–3590. (10.1210/jc.2002-021172) PubMed DOI

van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. Journal of Clinical Endocrinology and Metabolism 2003. 88 1119–1125. (10.1210/jc.2002-021171) PubMed DOI

Darendeliler F, Lindberg A, Wilton P. Response to growth hormone treatment in isolated growth hormone deficiency versus multiple pituitary hormone deficiency. Hormone Research in Paediatrics 2011. 76 (Supplement 1) 42–46. (10.1159/000329161) PubMed DOI

Lee PA, Germak J, Gut R, Khutoryansky N, Ross J. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program(®). International Journal of Pediatric Endocrinology 2011. 2011 6 (10.1186/1687-9856-2011-6) PubMed DOI PMC

Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry 2011. 57 555 (10.1373/clinchem.2010.150631) PubMed DOI

Pawlikowska-Haddal A, Cohen P, Cook DM. How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? Pituitary 2012. 15 126–134. (10.1007/s11102-011-0343-y) PubMed DOI

Cassorla F, Cianfarani S, Haverkamp F, Labarta JI, Loche S, Luo X, Maghnie M, Mericq V, Muzsnai A, Norgren S, et al. Growth hormone and treatment outcomes: expert review of current clinical practice. Pediatric Endocrinology Reviews 2011. 9 554–565. PubMed

Juul A, Bernasconi S, Clayton PE, Kiess W, DeMuinck-Keizer Schrama S. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Hormone Research 2002. 58 233–241. (10.1159/000066265) PubMed DOI

Wyatt DT, Mark D, Slyper A. Survey of growth hormone treatment practices by 251 pediatric endocrinologists. Journal of Clinical Endocrinology and Metabolism 1995. 80 3292–3297. (10.1210/jcem.80.11.7593441) PubMed DOI

Höybye C, Sävendahl L, Christesen HT, Lee P, Pedersen BT, Schlumpf M, Germak J, Ross J. The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). Clinical Epidemiology 2013. 5 119–127. (10.2147/clep.s42602) PubMed DOI PMC

Public Policy Committee ISoP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiology and Drug Safety 2016. 25 2–10. (10.1002/pds.3891) PubMed DOI

Christesen HT, Pedersen BT, Pournara E, Petit IO, Juliusson PB. Short stature: comparison of WHO and national growth standards/references for height. PLoS ONE 2016. 11 e0157277 (10.1371/journal.pone.0157277) PubMed DOI PMC

Sempé M, Pédron G, Roy-Pernot MP. Auxologie, Méthode et Séquences. Paris: Théraplix, 1979.

Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Statistics in Medicine 1998. 17 407–429. (10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO;2-L) PubMed DOI

World Health Organization. WHO Child Growth Standards: Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva: WHO, 2006.

Kobzova J, Vignerova J, Blaha P, Krejcovsky L, Riedlova J. The 6th nationwide anthropological survey of children and adolescents in the Czech Republic in 2001. Central European Journal of Public Health 2004. 12 126–130. PubMed

Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiß CH, Hesse V, von Hippel A, Jaeger U, Johnsen D, Korte W, et al. Perzentile für den body-mass-index für das kindes- und jugendalter unter heranziehung verschiedener deutscher stichproben. Monatsschrift Kinderheilkunde 2001. 149 807–818. (10.1007/s001120170107) DOI

Betts P, Butler G, Donaldson M, Dunger D, Johnston D, Kelnar C, Kirk J, Price D, Wilton P. A decade of growth hormone treatment in girls with Turner syndrome in the UK. Archives of Disease in Childhood 1999. 80 221–225. (10.1136/adc.80.3.221) PubMed DOI PMC

Cappa M, Iughetti L, Loche S, Maghnie M, Vottero A. Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study. Journal of Endocrinological Investigation 2016. 39 667–677. (10.1007/s40618-015-0418-0) PubMed DOI PMC

Pfaffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope((R)) in children requiring growth hormone treatment. Therapeutic Advances in Endocrinology and Metabolism 2013. 4 3–11. (10.1177/2042018813479644) PubMed DOI PMC

Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA, KIGS International Board Kabi International Growth Study. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. Journal of Clinical Endocrinology and Metabolism 2000. 85 4212–4218. (10.1210/jcem.85.11.6976) PubMed DOI

Bondy CA. & Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. Journal of Clinical Endocrinology and Metabolism 2007. 92 10–25. (10.1210/jc.2006-1374) PubMed DOI

Radetti G, Pasquino B, Gottardi E, Boscolo Contadin I, Aimaretti G, Rigon F. Insulin sensitivity in Turner’s syndrome: influence of GH treatment. European Journal of Endocrinology 2004. 151 351–354. (10.1530/eje.0.1510351) PubMed DOI

Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2008. 93 2109–2114. (10.1210/jc.2007-2266) PubMed DOI PMC

Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Journal of Clinical Endocrinology and Metabolism 2000. 85 3653–3660. (10.1210/jcem.85.10.6906) PubMed DOI

Boonstra V, van Pareren Y, Mulder P, Hokken-Koelega A. Puberty in growth hormone-treated children born small for gestational age (SGA). Journal of Clinical Endocrinology and Metabolism 2003. 88 5753–5758. (10.1210/jc.2003-030512) PubMed DOI

Devesa J, Almengló C, Devesa P. Multiple effects of growth hormone in the body: is it really the hormone for growth? Clinical Medicine Insights: Endocrinology and Diabetes 2016. 9 47–71. (10.4137/CMED.S38201) PubMed DOI PMC

Ross J, Czernichow P, Biller BM, Colao A, Reiter E, Kiess W. & Advisory Panel Meeting on the Effects of Growth Hormone. Growth hormone: health considerations beyond height gain. Pediatrics 2010. 125 e906–e918. (10.1542/peds.2009-1783) PubMed DOI

Nyberg F, Hallberg M. Growth hormone and cognitive function. Nature Reviews Endocrinology 2013. 9 357–365. (10.1038/nrendo.2013.78) PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00960128